Urol. praxi. 2024;25(4):180-184 | DOI: 10.36290/uro.2024.068

New approaches in the treatment of testicular cancer

MUDr. Pavel Navrátil, FEBU1, 2, MUDr. Minh Nguyet Tranová1, MUDr. Jiří ©paček, FEBU1, 2, MUDr. Michal Balík, Ph.D.1, 2, doc. MUDr. Jaroslav Pacovský, Ph.D.1, 2
1 Urologická klinika, Fakultní nemocnice Hradec Králové
2 Lékařská fakulta v Hradci Králové, Univerzita Karlova

Testicular germ cell tumors represent a significant challenge in the field of oncology, despite their relatively low incidence. This article focuses on current approaches in their treatment, emphasizing the optimization of care and minimizing the risk of relapse and treatment toxicity. Standard procedures such as orchiectomy, chemotherapy, radiotherapy, and lymphadenectomy are discussed. Special attention is given to the role of new biomarkers, such as miR-371a-3p, which improve the accuracy of diagnosis and treatment monitoring. The article also reflects current trends in therapy de-escalation and research of new targeted therapeutic approaches, including currently studied substances and drug combinations. There is a need for a personalized approach in the treatment of these tumors allowing better outcomes while reducing side effects of the therapy.

Keywords: testicular cancer, orchiectomy, chemotherapy, radiotherapy.

Accepted: November 11, 2024; Published: November 25, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Navrátil P, Nguyet Tranová M, ©paček J, Balík M, Pacovský J. New approaches in the treatment of testicular cancer. Urol. praxi. 2024;25(4):180-184. doi: 10.36290/uro.2024.068.
Download citation
PDF will be unlocked 25.11.2025

References

  1. Park JS, Kim J, Elghiaty A, et al. Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore). 2018;97(37):e12390. Go to original source... Go to PubMed...
  2. Nigam M, Aschebrook-Kilfoy B, Shikanov S, et al. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol. 2015;33(5):623-631. Go to original source... Go to PubMed...
  3. Gurney JK, Florio AA, Znaor A, et al. International Trends in the Incidence of Testicular Cancer: Lessons from 35 Years and 41 Countries. Eur Urol. 2019;76(5):615-623. Go to original source... Go to PubMed...
  4. Nicol D, Berney DM, Boormans JL, et al. EAU Guidelines on Testicular Cancer, presented at the EAU Annual Congress Paris 2024.
  5. Huang J, Chan SC, Tin MS, et al. Worldwide Distribution, Risk Factors, and Temporal Trends of Testicular Cancer Incidence and Mortality: A Global Analysis. Eur Urol Oncol. 2022;5(5):566-576. Go to original source... Go to PubMed...
  6. Oosterhuis JW, Looijenga LHJ. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer. 2005;5(3):210-222. Go to original source... Go to PubMed...
  7. ÚZIS. Cancer incidence 2019-2021 in the Czech Republic.
  8. Patel HD, Gupta M, Cheaib JG, et al. Testis-sparing surgery and scrotal violation for testicular masses suspicious for malignancy: A systematic review and meta-analysis. Urol Oncol. 2020;38(5):344-353. Go to original source... Go to PubMed...
  9. Skoogh J, Steineck G, Cavallin-Ståhl E, et al. Feelings of loss and uneasiness or shame after removal of a testicle by orchidectomy: a population-based long-term follow-up of testicular cancer survivors. Int J Androl. 2011;34(2):183-192. Go to original source... Go to PubMed...
  10. Gilligan T, Lin DW, Aggarwal R, et al. Testicular Cancer, Version 1.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2024;17(12):1529-1554. Go to original source... Go to PubMed...
  11. Dieckmann K-P, Kulejewski M, Pichlmeier U, et al. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol. 2007;51(1):175-183;discussion 183-185. Go to original source... Go to PubMed...
  12. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, et al. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol Off J Eur Soc Med Oncol. 2005;16(6):863-868. Go to original source... Go to PubMed...
  13. Dieckmann K-P, Wilken S, Loy V, et al. Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: a survey of the German Testicular Cancer Study Group. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(5):1332-1337. Go to original source... Go to PubMed...
  14. Mortensen MS, Gundgaard MG, Daugaard G. Treatment options for carcinoma in situ testis. Int J Androl. 2011;34(4 Pt 2):e32-36. Go to original source... Go to PubMed...
  15. Warde P, Specht L, Horwich A, et al. Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis. J Clin Oncol. 2002;20(22):4448-4452. Go to original source... Go to PubMed...
  16. Mortensen MS, Lauritsen J, Gundgaard MG, et al. A Nationwide Cohort Study of Stage I Seminoma Patients Followed on a Surveillance Program. Eur Urol. 2014;66(6):1172-1178. Go to original source... Go to PubMed...
  17. Chovanec M, Cheng L. Advances in diagnosis and treatment of testicular cancer. BMJ. 2022; e070499. Go to original source... Go to PubMed...
  18. Coleman JM, Coleman RE, Turner AR, et al. The management and clinical course of testicular seminoma: 15 years' experience at a single institution. Clin Oncol (R Coll Radiol). 1998;10(4):237-241. Go to original source... Go to PubMed...
  19. Santoni R, Barbera F, Bertoni F, et al. Stage I seminoma of the testis: a bi-institutional retrospective analysis of patients treated with radiation therapy only. BJU Int. 2003;92(1):47-52; discussion 52. Go to original source... Go to PubMed...
  20. Jones WG, Fossa SD, Mead GM, et al. Randomized Trial of 30 Versus 20 Gy in the Adjuvant Treatment of Stage I Testi­cular Seminoma: A Report on Medical Research Council Trial TE18, European Organisation for the Research and Treat­ment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005;23(6):1200-1208. Go to original source... Go to PubMed...
  21. Travis LB, Ng AK, Allan JM, et al. Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy. JNCI J Natl Cancer Inst. 2012;104(5):357-370. Go to original source... Go to PubMed...
  22. Hellesnes R, Myklebust TÅ, Fosså SD, et al. Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort. J Clin Oncol. 2021;39(32):3561-3573. Go to original source... Go to PubMed...
  23. Oliver RTD, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet (London, England). 366(9482):293-300.
  24. Albers P, Siener R, Kliesch S, et al. Risk Factors for Relapse in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: Results of the German Testicular Cancer Study Group Trial. J Clin Oncol. 2003;21(8):1505-1512. Go to original source... Go to PubMed...
  25. Sweeney CJ, Hermans BP, Heilman DK, et al. Results and Outcome of Retroperitoneal Lymph Node Dissection for Clinical Stage I Embryonal Carcinoma - Predominant Testis Can­cer. J Clin Oncol. 2000;18(2):358-358. Go to original source... Go to PubMed...
  26. Blok JM, Pluim I, Daugaard G, et al. Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis. BJU Int. 2020;125(3):355-368. Go to original source... Go to PubMed...
  27. Tandstad T, Ståhl O, Håkansson U, et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol. 2014;25(11):2167-2172. Go to original source... Go to PubMed...
  28. Albers P, Siener R, Krege S, et al. Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94. J Clin Oncol. 2008;26(18):2966-2972. Go to original source... Go to PubMed...
  29. Beck SDW, Bey AL, Bihrle R, et al. Ejaculatory Status and Fertility Rates After Primary Retroperitoneal Lymph Node Dissection. J Urol. 2010;184(5):2078-2080. Go to original source... Go to PubMed...
  30. Classen J, Schmidberger H, Meisner C, et al. Radiotherapy for Stages IIA/B Testicular Seminoma: Final Report of a Pros­pective Multicenter Clinical Trial. J Clin Oncol. 2003;21(6): 1101-1106. Go to original source... Go to PubMed...
  31. Domont J, Massard C, Patrikidou A, et al. A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. Urol Oncol Semin Orig Investig. 2013;31(5):697-705. Go to original source... Go to PubMed...
  32. Heinzelbecker J, Schmidt S, Lackner J, et al. Therapy of clinical stage IIA and IIB seminoma: a systematic review. World J Urol. 2022;40(12):2829-2841. Go to original source... Go to PubMed...
  33. Giannatempo P, Greco T, Mariani L, et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(4):657-668. Go to original source... Go to PubMed...
  34. Daneshmand S, Cary C, Masterson T, et al. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J Clin Oncol. 2023;41(16):3009-3018. Go to original source... Go to PubMed...
  35. Hiester A, Che Y, Lusch A, et al. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). Eur Urol. 2023;84(1):25-31. Go to original source... Go to PubMed...
  36. Loriot Y, Texier M, Culine S, et al. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Eur Urol. 2022;82(2):172-179. Go to original source... Go to PubMed...
  37. Nicolai N, Nazzani S, Tesone A, et al. Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacy. Tumori. 2023;109(4):379-386. Go to original source... Go to PubMed...
  38. Bokemeyer C, Kollmannsberger C, Stenning S, et al. Meta­static seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer. 2004;91(4):683-687. Go to original source... Go to PubMed...
  39. King J, Dropcho S, Beeler S, et al. A phase II trial evaluating the efficacy of cabozantinib in the treatment of patients with refractory germ-cell tumors (GCT). J Clin Oncol. 2022;40(6_suppl):TPS428-TPS428. Go to original source...
  40. Necchi A, Anichini A, Raggi D, et al. Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure. Clin Genitourin Cancer. 2016;14(4):261-264.e4. Go to original source... Go to PubMed...
  41. Albany C, Fazal Z, Singh R, et al. A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer. Cancer Med. 2021;10(1):156-163. Go to original source... Go to PubMed...
  42. Tandstad T, Stahl O, Dahl O, et al. The ABC-study: A randomized phase III study comparing one course of adjuvant bleomycin, etoposide, and cisplatin (BEP) and one course of carboplatin AUC7 in clinical stage I seminomatous testicular cancer. J Clin Oncol. 2017;35(15_suppl): TPS4593-TPS4593. Go to original source...
  43. Swiss Group for Clinical Cancer Research. Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma. NCT03937843.
  44. Feliciani G, Mellini L, Carnevale A, et al. The potential role of MR based radiomic biomarkers in the characterization of focal testicular lesions. Sci Rep. 2021;11(1):3456. Go to original source... Go to PubMed...
  45. Lobo J, Zogchel LMJ van, Nuru MG, et al. Combining Hypermethylated RASSF1A Detection Using ddPCR with miR-371a-3p Testing: An Improved Panel of Liquid Biopsy Biomarkers for Testicular Germ Cell Tumor Patients. Cancers (Basel). 2021;13(20):5228. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.